These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 30595243)

  • 1. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
    Ramakumari N; Indumathi B; Katkam SK; Kutala VK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
    Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
    Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
    Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
    Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
    Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS.
    Dheyaa Aziz N; Abbood SH; Al-Mayali AH; Hadi NR
    Pol Merkur Lekarski; 2023; 51(5):496-503. PubMed ID: 38069850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms.
    Linskey DW; English JD; Perry DA; Ochs-Balcom HM; Ma C; Isackson PJ; Vladutiu GD; Luzum JA
    Pharmacogenet Genomics; 2020 Dec; 30(9):208-211. PubMed ID: 32453264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
    Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
    Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and statin-related myopathy: what do we know?
    Turner RM; Radman I; Bozina N; Alfirevic A
    Pharmacogenomics; 2020 Aug; 21(12):821-825. PubMed ID: 32723135
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
    Lu B; Sun L; Seraydarian M; Hoffmann TJ; Medina MW; Risch N; Iribarren C; Krauss RM; Oni-Orisan A
    Clin Pharmacol Ther; 2021 Sep; 110(3):733-740. PubMed ID: 34114646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
    Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
    Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke.
    Zhang L; Lv H; Zhang Q; Wang D; Kang X; Zhang G; Li X
    Curr Pharm Des; 2019; 25(14):1663-1670. PubMed ID: 31298164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    ; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
    N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
    Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
    Carr DF; O'Meara H; Jorgensen AL; Campbell J; Hobbs M; McCann G; van Staa T; Pirmohamed M
    Clin Pharmacol Ther; 2013 Dec; 94(6):695-701. PubMed ID: 23942138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy.
    Neřoldová M; Stránecký V; Hodaňová K; Hartmannová H; Piherová L; Přistoupilová A; Mrázová L; Vrablík M; Adámková V; Hubáček JA; Jirsa M; Kmoch S
    Pharmacogenomics; 2016 Aug; 17(13):1405-14. PubMed ID: 27296017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.
    Sivkov A; Chernus N; Gorenkov R; Sivkov S; Sivkova S; Savina T
    Lipids Health Dis; 2021 Nov; 20(1):157. PubMed ID: 34749751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.